Randomized comparison of biodegradable polymer sirolimus-eluting stents versus durable polymer everolimus-eluting stents for percutaneous coronary revascularization: Rationale and design of the BIOSCIENCE trial, ABSTRACT Background: Biodegradable polymers for release of antiproliferative drugs from metallic drug-eluting stents (DES) aim to improve long-term vascular healing and efficacy. We designed a large scale clinical trial to compare a novel thin strut, cobalt chromium DES with silicon carbide coating releasing sirolimus from a biodegradable polymer (Orsiro, O-SES) with the durable polymer-based Xience Prime everolimus-eluting stent (X-EES) in an all-comers patient population.
BACKGROUND
Early generation drug-eluting stents (DES) have significantly reduced neointimal hyperplasia and the need for repeat revascularizations compared with bare metal stents (1) . The reduction in restenosis came at the expense of an increased risk of very late stent thrombosis (2) , motivating the development of newer generation devices. DES typically consist of three components: a metal scaffold, an antiproliferative agent, and a polymer matrix controlling the release of the drug.
Modifications and technical refinements of each of the three components have contributed to an improvement in safety and efficacy of DES in recent years. New generation DES with thin strut stent platforms, biocompatible polymers and lower dosages of limus-analogues largely eliminated the risk of very late stent thrombosis while maintaining the antirestenotic efficacy of early generation DES (3, 4) .
The polymer matrix of early generation DES has been shown to elicit an inflammatory response.
Histopathological analysis of very late stent thrombosis specimens showed evidence of localized hypersensitivity reactions with eosinophilic infiltrates and aggregates of giant cells around polymer fragments (5) . A prolonged inflammatory response to the polymer has hence been associated with delayed vascular healing with impaired stent strut endothelialization (6) and pathologic vessel remodeling resulting in coronary evaginations with secondary incomplete stent apposition (7) . Moreover, early generation DES have been associated with endothelial dysfunction (8) and an increased risk of neoatherosclerosis (9) compared with bare metal stents. Delayed vascular healing after implantation of early generation DES may not only be the underlying mechanism of very late stent thrombosis, but also explain the catch-up phenomenon of delayed late loss observed during long-term angiographic follow after DES implantation (10) . (11) . In the COMPARE II trial, biodegradable polymer biolimus-eluting stents proved non-inferior in direct comparison with durable polymer EES with respect to a composite of cardiac death, myocardial infarction and clinically-indicated target vessel revascularization at one year (12) . Similarly, the NEXT trial demonstrated no significant differences between biolimus-eluting stents with a biodegradable polymer and EES with a durable polymer with regard to the primary efficacy endpoint target lesion revascularization at one year (13) . Of note, all biodegradable polymer stents used in the trials mentioned above were based on stainless steel platforms with a strut thickness comparable to early generation DES and have not been combined with newer generation metallic platforms.
A series of randomized clinical trials comparing EES with early generation DES and zotarolimuseluting stents established EES as the current standard of care in terms of safety and efficacy (14) . The biodegradable polymer SES (Orsiro, Biotronik, Bülach, Switzerland) combines a biodegradable poly-L lactic (PLLA) polymer with an ultrathin strut (60 μm) cobalt-chromium L605 platform covered with an amorphous silicon-carbide layer. The SES with biodegradable polymer has been compared with durable polymer EES in a randomized controlled trial with angiographic follow-up and was shown to be non-inferior in terms of the primary endpoint in-stent late lumen loss at nine months (0.10 ± 0.31 mm vs. 0.11 ± 0.29 mm, p noninferiority <0.0001). Findings from optical coherence tomography and intravascular ultrasound showed adequate stent strut coverage in both groups and documented a smaller neointimal area in patients allocated to SES with a biodegradable polymer, respectively (15) .
We therefore designed a randomized controlled, non-inferiority trial comparing the biodegradable polymer SES with the durable polymer EES in an all-comers population with the primary clinical endpoint target-lesion failure (TLF).
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TRIAL DESIGN
Study Design and Primary Hypothesis
The BIOSCIENCE trial is a randomized, assessor blind, multicenter, non-inferiority trial comparing SES with biodegradable polymer (Orisro, O-SES) with EES with durable polymer (Xience prime/xpedition, X-EES) in an unselected patient population. The study protocol was designed by the steering committee (TP, PJ, SW), and all data were managed by the Clinical Trials Unit Bern, Switzerland. The trial is powered to investigate the study hypothesis that SES with biodegradable polymer are noninferior to durable polymer EES stents with respect to target lesion failure (TLF), defined as a composite of cardiac death, target vessel myocardial infarction (MI), and clinically driven target lesion revascularization (TLR) within 12 months.
Statistical Analysis
The sample size calculation was based on event rates reported in the COMPARE trial (12) , the RESOLUTE AC trial (16) , and the LESSON registry (3), assuming a TLF rate of 8% at 12 months in both treatment arms. A non-inferiority margin of 3.5% was defined for non-inferiority of the O-SES compared with the X-EES. Enrolment of 2060 patients was calculated to provide 80% power to detect non-inferiority at a one-sided type I error of 0.05. Clinical endpoints will be analyzed according to the intention-to-treat principle. Lesion-level data will be analysed using linear and logistic mixed effects models to account for the non-independence of measurements from the same patient.
Study Population
Patients eligible for PCI with at least one lesion of >50% diameter stenosis suitable for stent implantation qualified for enrolment. The inclusion and exclusion criteria are summarized in table 1.
All patients provided written informed consent.
Between March 2012 and May 2013, a total of 2,119 patients were randomly assigned to treatment with O-SES or X-EES at 9 centers in Switzerland. Random stent allocation was performed by means of an electronic web database "Cardiobase" (Copyright by Department of Cardiology, CTU Bern, Switzerland and 2mt software GmbH, Ulm, Germany) in a 1:1 ratio stratified according to center and presence or absence of ST -segment elevation myocardial infarction.
Procedure
PCI was performed according to current guidelines. Lesion preparation in terms of predilatation was left to the discretion of the operator. In case of multivessel disease, all lesions treated within the same or during a subsequent staged procedure had to be treated with the assigned study stent.
There was no restriction with regards to type or number of lesions.
Study Medications
Unfractionated heparin at a dose of at least 5000 IE or 70-100 IE/kg body weight was administered during the procedure. Alternative treatment with bivalirudin and administration of GpIIb/IIIa inhibitors was left to the discretion of the operator.
Patients were loaded with acetylsalicylic acid at a dosage of at least 250 mg prior to the procedure and with clopidogrel (recommended dosage of 600 mg), prasugrel (recommended dosage of 60 mg) or ticagrelor (recommended dosage of 180 mg) immediately following stent implantation.
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Combination of dual antiplatelet therapy was left to the discretion of the participating center. Dual antiplatelet therapy was continued for at least 6 months according to local practice.
Pre-specified Analyses
We will perform stratified analyses of the primary endpoint across major subgroups using the Mantel-Cox method. Subgroup analyses of the primary endpoint will be performed with respect to acute coronary syndrome status, acute ST-segment elevation myocardial infarction (also used as stratification during randomization), off-versus on-label indication, and diabetes. Rates of cerebrovascular events and bleeding complications will be analysed according to type and duration of antithrombotic and antiplatelet strategy.
Definitions
Target lesion failure (TLF) is defined as the composite of cardiac death, target vessel myocardial infarction, and clinically driven target lesion revascularization. All definitions are outlined in detail in the appendix. The clinical endpoints will be adjudicated by an independent event adjudication committee.
Data Collection
Patient data are collected in a web-based 
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ENDPOINT DEFINITIONS
Death
All deaths are considered cardiac unless an unequivocal non-cardiac cause can be established.
Cardiac death: Any death due to immediate cardiac cause (e.g. MI, low-output failure, fatal arrhythmia). Unwitnessed death and death of unknown cause will be classified as cardiac death.
Vascular death: Death due to cerebrovascular disease, pulmonary embolism, ruptured aortic aneurysm, dissecting aneurysm, or other vascular cause.
Non-cardiovascular death: Any death not covered by the above definitions, including death due to infection, sepsis, pulmonary causes, accident, suicide or trauma.
Myocardial infarction
Spontaneous MI is documented in case of a typical rise and gradual fall of biochemical markers in combination with either one of the following characteristics: ischemic symptoms, development of has not returned to <ULN are defined as periprocedural MI.
Target-vessel myocardial infarction
Target-vessel myocardial infarction is defined as any myocardial infarction that is not clearly attributable to a non-target-vessel.
Target-vessel
The target vessel is the index coronary artery which was in physical contact with any component (guiding catheter, guide wire, balloon catheter, etc.) of the angioplasty hardware during the initial procedure.
Target lesion
The target lesion is the treated lesion starting 5 mm proximal of the stented lesion and to end 5 mm distal of the stented lesion.
Target lesion revascularization
Target lesion revascularization (TLR) is defined as any repeat percutaneous intervention of the target lesion or bypass surgery of the target vessel. TLRs are documented as clinically-indicated if repeat angiography shows a percent diameter stenosis ≥50% and the patients has a history of recurrent angina, objective signs of ischemia, or abnormal results of any invasive functional diagnostic tests.
TLRs for percent diameter stenosis ≥70% are considered clinically significant even in the absence of the above-mentioned criteria.
Device success
Device success is defined as the attainment of <30% residual stenosis by QCA (or <20% by visual assessment), using the assigned device only.
Lesion success
Lesion success is define as the attainment of <30% residual stenosis by QCA (or <20% by visual assessment), using any percutaneous method.
Procedural success
Procedural success is defined as the attainment of <30% residual stenosis by QCA (or <20% by visual assessment) in all lesions using any percutaneous method , without the occurrence of death, MI, or repeat revascularization of the target vessel during the hospital stay.
Stent thrombosis
Stent thrombosis is categorized into definite, probable and possible according to the definition provided by the Academic Research Consortium (17).
Bleeding
Bleeding complications will be defined in accordance with the BARC criteria (18) .
